Celgene Corp (CELGZ) 3.17 $CELGZ
Celgene Announces Positive Recommendation by Scottish Medicines Consortium (SMC) for ABRAXANE(R) (Nab-Paclitaxel) in combination with Gemcitabine(1) for Patients with Metastatic Pancreatic Cancer
Business Wire - Tue Feb 10, 1:02AM CST
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that ABRAXANE(R) (paclitaxel formulated as albumin-bound nanoparticles; nab-paclitaxel), in combination with gemcitabine, has now received a positive recommendation for the treatment of metastatic pancreatic cancer by the Scottish Medicines Consortium (SMC) within the National Health Service Scotland.(1) The decision follows the recent NHS England announcement to defer their review of ABRAXANE(R) for metastatic pancreatic cancer, allowing the treatment to remain on the National Cancer Drugs Fund (NCDF) list until a final decision is made.(2)
CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Critical Alerts For Juno Therapeutics Inc, Westport Innovations, Disney, Twitter and Celgene Released By InvestorsObserver
PR Newswire - Thu Feb 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JUNO, WPRT, DIS, TWTR and CELG.
WPRT: 6.06 (+0.26), DIS: 104.17 (+0.59), JUNO: 40.52 (+0.18), TWTR: 48.50 (+0.55), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Biotech Stocks Scanner - ARIAD Pharma, Celgene, CytRx, Amicus Therapeutics, and United Therapeutics
PR Newswire - Wed Feb 04, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Celgene Corporation (NASDAQ: CELG), CytRx Corporation (NASDAQ: CYTR), Amicus Therapeutics Inc. (NASDAQ: FOLD), and United Therapeutics Corporation (NASDAQ: UTHR). Free research report on ARIAD Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=ARIAD%20P...amp;s=ARIA. On Tuesday, February 03, 2015, the NASDAQ Composite ended at 4,727.74, up 1.09%, the Dow Jones Industrial Average advanced 1.76%, to finish the day at 17,666.40, and the S&P 500 closed at 2,050.03, up 1.44%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 811.48, up 0.65%, with the index also advancing 4.16% in the previous three months. Register for your complimentary reports at the links given below.
UTHR: 151.11 (+3.59), CYTR: 2.96 (+0.23), ARIA: 7.35 (+0.45), FOLD: 8.36 (-0.11), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Hematological Malignancies: Multiple Myeloma (MM) Market Report 2015
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/rsh8ph/hematological) has announced the addition of the "Hematological Malignancies: Multiple Myeloma (MM) " report to their offering. While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile? Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. This report highlights the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Key Topics Covered: 1. Executive Summary 2. Disease Overview, Diagnosis, and Current Treatment 3. Diagnostic Tools for Multiple Myeloma 4. M&A Deals and Market Opportunity in Diagnostic Space 5. Current Therapies 6. Novel Targets 7. Clinical Milestones 8. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline 9. M&A/ Licensing Deals and Unpartnered Product Opportunities Companies Mentioned - Abbott - Affymetrix - AgenaBio - Altor Bioscience - Amgen - Array Biopharma - Astex pharma (now Otsuka pharma) - BMS - Biotest pharma - Cancer Genetics Inc - Celgene - CureTech - GSK - Illumina - Immunogen - Innate Pharma - Innate Pharma - JNJ - Karyopharm Therapeutics - Lilly - Merck - MorphoSys - Mundipharma - NeoGenomics - Novartis - Pharmacyclics - Regulus Therapeutics - Rosetta Genomics - Sequenta - Takeda Pharma For more information visit http://www.researchandmarkets.com/research/rs...atological
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), CGIX: 7.07 (unch), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Celgene Reports Fourth Quarter and Full Year 2014 Operating and Financial Results
Business Wire - Thu Jan 29, 6:30AM CST
--- 2015 Guidance and 2020 Financial Targets Provided
CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Celgene Corporation to Webcast at Upcoming Investor Conferences
Business Wire - Tue Jan 27, 7:30AM CST
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.celgene.com.
CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Lung Cancer Clinical Trial Overview 2014
M2 - Fri Jan 23, 9:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/9ww7kn/lung_cancer) has announced the addition of the "Lung Cancer Clinical Trial Overview" report to their offering. This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial metrics: - Phase of study - Study type distribution (expanded access, interventional, observational) - Length of trials - Patient enrollment - Study sponsors - Regional breakdown Major Sections: - Introduction - Lung Cancer Clinical Trial Analysis - Average Clinical Trial Enrollment - Study Sponsor Analysis by Phase - Regional Analysis How you can use this report: - Identify how products currently in development could impact this market and understand competitor involvement by using detailed information on current late phase lung cancer trials - Benchmark your study length and patient enrollment metrics against industry-wide, phase-specific, and study type-specific averages - Plan your clinical trial strategy better by understanding where industry-funded lung cancer trial sites are located globally Key Topics Covered: 1. Introduction 2. Lung cancer clinical trial analysis 3. Average length of clinical trials 4. Average Clinical Trial Enrollment 5. Study sponsor analysis by Phase 6. Regional analysis Companies Mentioned - Actavis - Agennix - Amgen - AstraZeneca - Betta Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene Corporation - Chong Kun Dang Pharmaceutical - Eisai - Eli Lilly and Company - EMD Serono - Genentech - Gilead Sciences - GlaxoSmithKline - Helsinn Therapeutics (U.S.) - Hoffmann-La Roche - J. Uriach and Company - Janssen Korea - Jiangsu HengRui Medicine Co. - Kael-GemVax Co. - Merck KGaA - Novartis Pharmaceuticals - Peregrine Pharmaceuticals - Pfizer - Pierre Fabre Pharma GmbH - Sanofi - Swami Rama Cancer Hospital and Research Institute - Synta Pharmaceuticals - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/9w...ung_cancer
AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), SNTA: 2.29 (-0.03), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
Celgene Receives Positive CHMP Opinion for ABRAXANE(R) for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
Business Wire - Fri Jan 23, 6:19AM CST
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ABRAXANE(R) (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Acetylon Presents at the Wells Fargo Celgene Partnership Forum
Business Wire - Wed Jan 21, 1:47PM CST
Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that Walter C. Ogier, President and Chief Executive Officer of Acetylon, participated in the Wells Fargo Celgene Partnership Forum. Mr. Ogier discussed Acetylon's pipeline of selective HDAC inhibitors this morning on the panel entitled, "Express Yourself: Using Epigenetics to Transform Cancer Treatment." In addition, Mr. Ogier gave a presentation highlighting the positive preclinical and clinical data presented at the 2014 American Society of Hematology Annual Meeting and the progression of Acetylon's lead HDAC6 inhibitor, ricolinostat, into Phase 2 clinical studies for the treatment of multiple myeloma and for the treatment of lymphoma.
WFC: 55.33 (+0.47), CELGZ: 3.17 (-0.04)
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter
PR Newswire - Wed Jan 21, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Alcoa (NYSE:AA), Southwestern Energy (NYSE:SWN), Celgene (NASDAQ:CELG), Micron (NASDAQ:MU), FXCM (NYSE:FXCM), and Twitter (NYSE:TWTR).
MU: 31.85 (-0.09), AA: 15.81 (+0.16), FXCM: 2.21 (-0.01), TWTR: 48.50 (+0.55), SWN: 27.36 (+0.51), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Zymeworks Announces Bi-Specific Antibody Collaboration with Celgene
Business Wire - Wed Jan 21, 6:00AM CST
Zymeworks Inc. today announced a collaboration and licensing agreement with Celgene Corp. for the research, development, and commercialization of bi-specific antibody therapeutics enabled using Zymeworks' proprietary Azymetric(TM) platform.
CELGZ: 3.17 (-0.04)
Oral OTEZLA(R) (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis
Business Wire - Fri Jan 16, 11:24AM CST
Celgene International Sarl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation for OTEZLA(R) (apremilast), the company's oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications
1)
CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Companion Diagnostics Partnering Terms & Agreements Report 2014 (Updated Edition)
M2 - Fri Jan 16, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgqn4/companion) has announced the addition of the "Companion Diagnostics Partnering Terms & Agreements" report to their offering. The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Report scope Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide. Companion Diagnostics Partnering Terms and Agreements includes: - Trends in companion diagnostics dealmaking in the biopharma industry since 2009 - Analysis of companion diagnostics deal structure - Access to headline, upfront, milestone and royalty data - Case studies of real-life companion diagnostics deals - Access to companion diagnostics contract documents - The leading companion diagnostics deals by value since 2009 - Most active companion diagnostics dealmakers since 2009 - The leading companion diagnostics partnering resources In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by: - Company A-Z - Headline value - Stage of development at signing - Deal component type - Specific therapy target The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 250 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following: - What are the precise companion diagnostics rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Companies Mentioned - Abbott - Amgen - Astellas - AstraZeneca - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Chugai Pharmaceutical - Eisai - Eli Lilly - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Novartis - Pfizer - Roche - Sanofi - Servier - Takeda - UCB For more information visit http://www.researchandmarkets.com/research/kwgqn4/companion
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
The Market for Personalized Gene Therapy Treatments for Cancer
M2 - Fri Jan 16, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ddkrc/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering. This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. In addition the report provides: - Overview of Gene Therapy - Overall Market Size and Forecast - Cancer Therapeutic Market Totals - Discussion of Somati vs. Germ Line Gene Therapy - R&D Activities - Company Profiles Key Topics Covered: - Executive Summary - Gene Therapy Overview - Cancer and Gene Therapy - Gene Therapy Outlook in Bladder Cancer - Gene Therapy Outlook in Brain Cancer - Gene Therapy Outlook in Breast Cancer - Gene Therapy Outlook in Colorectal Cancer - Gene Therapy Outlook in Head & Neck Cancer - Gene Therapy Outlook in Leukemia - Gene Therapy Outlook in Liver Cancer - Gene Therapy Outlook in Lung Cancer - Gene Therapy Outlook in Lymphoma - Gene Therapy Outlook in Melanoma - Gene Therapy Outlook in Ovarian Cancer - Gene Therapy Outlook in Pancreatic Cancer - Gene Therapy Outlook in Prostate Cancer - Gene Therapy and Other Cancers - Gene Therapy in Cancer Market Summary and Outlook - Industry Participants and Contributors Companies Mentioned - Advantagene, Inc. - Amgen, Inc. - Bellicum Pharmaceuticals, Inc. - BioCancell Ltd. - Blubird Bio - Celgene - Celsion Corporation - Chengdu Shi Endor Biological Engineering Technology Co., Ltd. - Cold Genesys, Inc. - Genprex, Inc. - MaxiVax SA - Momotaro-Gene, Inc. - MultiVir, Inc. - OncoSec Medical, Inc. - Sevion Therapeutics, Inc. - SynerGene Therapeutics, Inc. - Takara Bio, Inc. - Tocagen, Inc. - VBL Therapeutics Ltd. - Ziopharm Oncology, Inc. - daptimmune Ltd. For more information visit http://www.researchandmarkets.com/research/9d...market_for
CLSN: 2.41 (+0.09), BLCM: 20.00 (-0.81), AMGN: 153.48 (+0.30), CELGZ: 3.17 (-0.04)
Research and Markets: Global Acute Myeloid Leukemia Therapeutics Market 2015-2019 With Bristol Myers Squibb, Celgene, Johnson & Johnson & Pfizer Dominating
Business Wire - Thu Jan 15, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b68lx/global_acute) has announced the addition of the "Global Acute Myeloid Leukemia Therapeutics Market 2015-2019" report to their offering.
JNJ: 99.62 (+1.18), CELGZ: 3.17 (-0.04)
Global Acute Myeloid Leukemia Therapeutics Market 2015-2019 with Bristol Myers Squibb, Celgene, Johnson & Johnson & Pfizer Dominating
M2 - Thu Jan 15, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/vvzt3d/global_acute) has announced the addition of the "Global Acute Myeloid Leukemia Therapeutics Market 2015-2019" report to their offering. The Global Acute Myeloid Leukemia Therapeutics market to grow at a CAGR of 19.75% over the period 2014-2019 Acute myeloid leukemia, also known as acute myelogenous leukemia, is a hematopoietic disorder that starts either in hematopoietic stem cells or lineage-specific progenitor cells. Neoplasms arise from bone marrow, however, it spreads quickly into the blood. In the later stages of the disorder, it spreads to spleen, lymph node, liver, brain, spinal cord and testicles. Clonal expansion of the myeloid blasts and the loss of normal hematopoiesis are the main characteristic of acute myeloid leukemia. The expected entry of novel drugs to treat acute myeloid leukemia is one major trend upcoming in this market. It is expected to be the preferred treatment option among the medical fraternity, patients, and families of patients. This is expected to increase the number of treatment-seeking patients, which is expected to result in an increase in the overall consumption of medicines. According to the report, the presence of high unmet needs with regard to the availability of appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely and, hence, the mortality rate is high. Therefore, drugs that can effectuate remission of the disease in patients are expected to drive the growth of the market. Further, the report states that the high cost of treatment is one of the major challenges hindering the growth of the market. Drugs used for the treatment of cancer are expensive and, hence, get a poor response from patients. The patients also tend to withdraw from expensive treatment regimens. For more information visit http://www.researchandmarkets.com/research/vv...obal_acute
JNJ: 99.62 (+1.18), CELGZ: 3.17 (-0.04)
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's
PR Newswire - Wed Jan 14, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Netlist (NASDAQ: NLST), Celgene (NASDAQ: CELG), Jamba (NASDAQ: JMBA), Citigroup (NYSE: C), and Tilly's (NYSE: TLYS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
TLYS: 13.08 (-0.19), NLST: 1.86 (unch), C: 51.20 (+0.31), JMBA: 14.50 (-0.61), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration
GlobeNewswire - Mon Jan 12, 3:11PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that its collaboration partner Celgene Corporation has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein under the terms of the 2010 collaboration agreement. This would be the second IDH mutant inhibitor to be licensed by Celgene in less than a year. AG-120 is currently being evaluated in two Phase 1 dose escalation trials, one in advanced hematologic malignancies and the other in advanced solid tumors. Both trials are evaluating AG-120 in patients whose cancer harbors an IDH1 mutation. The first data from the AG-120 program were presented at the EORTC-NCI-AACR Symposium on November 19, 2014 in advanced hematologic malignancies. Agios expects to report the first data from the Phase 1 advanced solid tumor trial at a medical conference in 2015. Celgene's exercise of the option is subject to receipt of any required regulatory approvals including any applicable clearance under the Hart-Scott-Rodino Act. Agios is webcasting its corporate presentation from the 33 Annual J.P. Morgan Healthcare Conference today at 2:30 p.m. PST (5:30 p.m. EST). The presentation will be followed by a webcast of its question and answer session at 3:00 p.m. PST (6:00 p.m. EST).
JPM: 59.67 (+0.10), AGIO: 118.55 (+0.11), CELGZ: 3.17 (-0.04)
Celgene Announces Positive Recommendation by Scottish Medicines Consortium (SMC) for ABRAXANE(R) (Nab-Paclitaxel) in combination with Gemcitabine(1) for Patients with Metastatic Pancreatic Cancer
Business Wire - Tue Feb 10, 1:02AM CST
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that ABRAXANE(R) (paclitaxel formulated as albumin-bound nanoparticles; nab-paclitaxel), in combination with gemcitabine, has now received a positive recommendation for the treatment of metastatic pancreatic cancer by the Scottish Medicines Consortium (SMC) within the National Health Service Scotland.(1) The decision follows the recent NHS England announcement to defer their review of ABRAXANE(R) for metastatic pancreatic cancer, allowing the treatment to remain on the National Cancer Drugs Fund (NCDF) list until a final decision is made.(2)
CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Critical Alerts For Juno Therapeutics Inc, Westport Innovations, Disney, Twitter and Celgene Released By InvestorsObserver
PR Newswire - Thu Feb 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JUNO, WPRT, DIS, TWTR and CELG.
WPRT: 6.06 (+0.26), DIS: 104.17 (+0.59), JUNO: 40.52 (+0.18), TWTR: 48.50 (+0.55), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Biotech Stocks Scanner - ARIAD Pharma, Celgene, CytRx, Amicus Therapeutics, and United Therapeutics
PR Newswire - Wed Feb 04, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Celgene Corporation (NASDAQ: CELG), CytRx Corporation (NASDAQ: CYTR), Amicus Therapeutics Inc. (NASDAQ: FOLD), and United Therapeutics Corporation (NASDAQ: UTHR). Free research report on ARIAD Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=ARIAD%20P...amp;s=ARIA. On Tuesday, February 03, 2015, the NASDAQ Composite ended at 4,727.74, up 1.09%, the Dow Jones Industrial Average advanced 1.76%, to finish the day at 17,666.40, and the S&P 500 closed at 2,050.03, up 1.44%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 811.48, up 0.65%, with the index also advancing 4.16% in the previous three months. Register for your complimentary reports at the links given below.
UTHR: 151.11 (+3.59), CYTR: 2.96 (+0.23), ARIA: 7.35 (+0.45), FOLD: 8.36 (-0.11), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Hematological Malignancies: Multiple Myeloma (MM) Market Report 2015
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/rsh8ph/hematological) has announced the addition of the "Hematological Malignancies: Multiple Myeloma (MM) " report to their offering. While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile? Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues. This report highlights the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Key Topics Covered: 1. Executive Summary 2. Disease Overview, Diagnosis, and Current Treatment 3. Diagnostic Tools for Multiple Myeloma 4. M&A Deals and Market Opportunity in Diagnostic Space 5. Current Therapies 6. Novel Targets 7. Clinical Milestones 8. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline 9. M&A/ Licensing Deals and Unpartnered Product Opportunities Companies Mentioned - Abbott - Affymetrix - AgenaBio - Altor Bioscience - Amgen - Array Biopharma - Astex pharma (now Otsuka pharma) - BMS - Biotest pharma - Cancer Genetics Inc - Celgene - CureTech - GSK - Illumina - Immunogen - Innate Pharma - Innate Pharma - JNJ - Karyopharm Therapeutics - Lilly - Merck - MorphoSys - Mundipharma - NeoGenomics - Novartis - Pharmacyclics - Regulus Therapeutics - Rosetta Genomics - Sequenta - Takeda Pharma For more information visit http://www.researchandmarkets.com/research/rs...atological
MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), CGIX: 7.07 (unch), NVS: 102.20 (-0.17), KPTI: 27.12 (-0.13), CELGZ: 3.17 (-0.04)
Celgene Reports Fourth Quarter and Full Year 2014 Operating and Financial Results
Business Wire - Thu Jan 29, 6:30AM CST
--- 2015 Guidance and 2020 Financial Targets Provided
CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Celgene Corporation to Webcast at Upcoming Investor Conferences
Business Wire - Tue Jan 27, 7:30AM CST
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.celgene.com.
CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Lung Cancer Clinical Trial Overview 2014
M2 - Fri Jan 23, 9:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/9ww7kn/lung_cancer) has announced the addition of the "Lung Cancer Clinical Trial Overview" report to their offering. This report provides insight into the current clinical trial activity surrounding lung cancer by examining industry-sponsored activities and quantifying important development milestones and trial metrics: - Phase of study - Study type distribution (expanded access, interventional, observational) - Length of trials - Patient enrollment - Study sponsors - Regional breakdown Major Sections: - Introduction - Lung Cancer Clinical Trial Analysis - Average Clinical Trial Enrollment - Study Sponsor Analysis by Phase - Regional Analysis How you can use this report: - Identify how products currently in development could impact this market and understand competitor involvement by using detailed information on current late phase lung cancer trials - Benchmark your study length and patient enrollment metrics against industry-wide, phase-specific, and study type-specific averages - Plan your clinical trial strategy better by understanding where industry-funded lung cancer trial sites are located globally Key Topics Covered: 1. Introduction 2. Lung cancer clinical trial analysis 3. Average length of clinical trials 4. Average Clinical Trial Enrollment 5. Study sponsor analysis by Phase 6. Regional analysis Companies Mentioned - Actavis - Agennix - Amgen - AstraZeneca - Betta Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene Corporation - Chong Kun Dang Pharmaceutical - Eisai - Eli Lilly and Company - EMD Serono - Genentech - Gilead Sciences - GlaxoSmithKline - Helsinn Therapeutics (U.S.) - Hoffmann-La Roche - J. Uriach and Company - Janssen Korea - Jiangsu HengRui Medicine Co. - Kael-GemVax Co. - Merck KGaA - Novartis Pharmaceuticals - Peregrine Pharmaceuticals - Pfizer - Pierre Fabre Pharma GmbH - Sanofi - Swami Rama Cancer Hospital and Research Institute - Synta Pharmaceuticals - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/9w...ung_cancer
AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), SNTA: 2.29 (-0.03), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
Celgene Receives Positive CHMP Opinion for ABRAXANE(R) for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
Business Wire - Fri Jan 23, 6:19AM CST
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ABRAXANE(R) (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Acetylon Presents at the Wells Fargo Celgene Partnership Forum
Business Wire - Wed Jan 21, 1:47PM CST
Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that Walter C. Ogier, President and Chief Executive Officer of Acetylon, participated in the Wells Fargo Celgene Partnership Forum. Mr. Ogier discussed Acetylon's pipeline of selective HDAC inhibitors this morning on the panel entitled, "Express Yourself: Using Epigenetics to Transform Cancer Treatment." In addition, Mr. Ogier gave a presentation highlighting the positive preclinical and clinical data presented at the 2014 American Society of Hematology Annual Meeting and the progression of Acetylon's lead HDAC6 inhibitor, ricolinostat, into Phase 2 clinical studies for the treatment of multiple myeloma and for the treatment of lymphoma.
WFC: 55.33 (+0.47), CELGZ: 3.17 (-0.04)
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter
PR Newswire - Wed Jan 21, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Alcoa (NYSE:AA), Southwestern Energy (NYSE:SWN), Celgene (NASDAQ:CELG), Micron (NASDAQ:MU), FXCM (NYSE:FXCM), and Twitter (NYSE:TWTR).
MU: 31.85 (-0.09), AA: 15.81 (+0.16), FXCM: 2.21 (-0.01), TWTR: 48.50 (+0.55), SWN: 27.36 (+0.51), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Zymeworks Announces Bi-Specific Antibody Collaboration with Celgene
Business Wire - Wed Jan 21, 6:00AM CST
Zymeworks Inc. today announced a collaboration and licensing agreement with Celgene Corp. for the research, development, and commercialization of bi-specific antibody therapeutics enabled using Zymeworks' proprietary Azymetric(TM) platform.
CELGZ: 3.17 (-0.04)
Oral OTEZLA(R) (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis
Business Wire - Fri Jan 16, 11:24AM CST
Celgene International Sarl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation for OTEZLA(R) (apremilast), the company's oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications
1) CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Companion Diagnostics Partnering Terms & Agreements Report 2014 (Updated Edition)
M2 - Fri Jan 16, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgqn4/companion) has announced the addition of the "Companion Diagnostics Partnering Terms & Agreements" report to their offering. The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Report scope Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide. Companion Diagnostics Partnering Terms and Agreements includes: - Trends in companion diagnostics dealmaking in the biopharma industry since 2009 - Analysis of companion diagnostics deal structure - Access to headline, upfront, milestone and royalty data - Case studies of real-life companion diagnostics deals - Access to companion diagnostics contract documents - The leading companion diagnostics deals by value since 2009 - Most active companion diagnostics dealmakers since 2009 - The leading companion diagnostics partnering resources In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by: - Company A-Z - Headline value - Stage of development at signing - Deal component type - Specific therapy target The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 250 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following: - What are the precise companion diagnostics rights granted or optioned? - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What is the payment structure for the deal? - How are sales and payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law? Companies Mentioned - Abbott - Amgen - Astellas - AstraZeneca - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Chugai Pharmaceutical - Eisai - Eli Lilly - GlaxoSmithKline - Johnson & Johnson - Merck & Co - Merck KGaA - Novartis - Pfizer - Roche - Sanofi - Servier - Takeda - UCB For more information visit http://www.researchandmarkets.com/research/kwgqn4/companion
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), MRK: 58.81 (-0.07), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
The Market for Personalized Gene Therapy Treatments for Cancer
M2 - Fri Jan 16, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ddkrc/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering. This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. In addition the report provides: - Overview of Gene Therapy - Overall Market Size and Forecast - Cancer Therapeutic Market Totals - Discussion of Somati vs. Germ Line Gene Therapy - R&D Activities - Company Profiles Key Topics Covered: - Executive Summary - Gene Therapy Overview - Cancer and Gene Therapy - Gene Therapy Outlook in Bladder Cancer - Gene Therapy Outlook in Brain Cancer - Gene Therapy Outlook in Breast Cancer - Gene Therapy Outlook in Colorectal Cancer - Gene Therapy Outlook in Head & Neck Cancer - Gene Therapy Outlook in Leukemia - Gene Therapy Outlook in Liver Cancer - Gene Therapy Outlook in Lung Cancer - Gene Therapy Outlook in Lymphoma - Gene Therapy Outlook in Melanoma - Gene Therapy Outlook in Ovarian Cancer - Gene Therapy Outlook in Pancreatic Cancer - Gene Therapy Outlook in Prostate Cancer - Gene Therapy and Other Cancers - Gene Therapy in Cancer Market Summary and Outlook - Industry Participants and Contributors Companies Mentioned - Advantagene, Inc. - Amgen, Inc. - Bellicum Pharmaceuticals, Inc. - BioCancell Ltd. - Blubird Bio - Celgene - Celsion Corporation - Chengdu Shi Endor Biological Engineering Technology Co., Ltd. - Cold Genesys, Inc. - Genprex, Inc. - MaxiVax SA - Momotaro-Gene, Inc. - MultiVir, Inc. - OncoSec Medical, Inc. - Sevion Therapeutics, Inc. - SynerGene Therapeutics, Inc. - Takara Bio, Inc. - Tocagen, Inc. - VBL Therapeutics Ltd. - Ziopharm Oncology, Inc. - daptimmune Ltd. For more information visit http://www.researchandmarkets.com/research/9d...market_for
CLSN: 2.41 (+0.09), BLCM: 20.00 (-0.81), AMGN: 153.48 (+0.30), CELGZ: 3.17 (-0.04)
Research and Markets: Global Acute Myeloid Leukemia Therapeutics Market 2015-2019 With Bristol Myers Squibb, Celgene, Johnson & Johnson & Pfizer Dominating
Business Wire - Thu Jan 15, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b68lx/global_acute) has announced the addition of the "Global Acute Myeloid Leukemia Therapeutics Market 2015-2019" report to their offering.
JNJ: 99.62 (+1.18), CELGZ: 3.17 (-0.04)
Global Acute Myeloid Leukemia Therapeutics Market 2015-2019 with Bristol Myers Squibb, Celgene, Johnson & Johnson & Pfizer Dominating
M2 - Thu Jan 15, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/vvzt3d/global_acute) has announced the addition of the "Global Acute Myeloid Leukemia Therapeutics Market 2015-2019" report to their offering. The Global Acute Myeloid Leukemia Therapeutics market to grow at a CAGR of 19.75% over the period 2014-2019 Acute myeloid leukemia, also known as acute myelogenous leukemia, is a hematopoietic disorder that starts either in hematopoietic stem cells or lineage-specific progenitor cells. Neoplasms arise from bone marrow, however, it spreads quickly into the blood. In the later stages of the disorder, it spreads to spleen, lymph node, liver, brain, spinal cord and testicles. Clonal expansion of the myeloid blasts and the loss of normal hematopoiesis are the main characteristic of acute myeloid leukemia. The expected entry of novel drugs to treat acute myeloid leukemia is one major trend upcoming in this market. It is expected to be the preferred treatment option among the medical fraternity, patients, and families of patients. This is expected to increase the number of treatment-seeking patients, which is expected to result in an increase in the overall consumption of medicines. According to the report, the presence of high unmet needs with regard to the availability of appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely and, hence, the mortality rate is high. Therefore, drugs that can effectuate remission of the disease in patients are expected to drive the growth of the market. Further, the report states that the high cost of treatment is one of the major challenges hindering the growth of the market. Drugs used for the treatment of cancer are expensive and, hence, get a poor response from patients. The patients also tend to withdraw from expensive treatment regimens. For more information visit http://www.researchandmarkets.com/research/vv...obal_acute
JNJ: 99.62 (+1.18), CELGZ: 3.17 (-0.04)
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's
PR Newswire - Wed Jan 14, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Netlist (NASDAQ: NLST), Celgene (NASDAQ: CELG), Jamba (NASDAQ: JMBA), Citigroup (NYSE: C), and Tilly's (NYSE: TLYS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
TLYS: 13.08 (-0.19), NLST: 1.86 (unch), C: 51.20 (+0.31), JMBA: 14.50 (-0.61), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration
GlobeNewswire - Mon Jan 12, 3:11PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that its collaboration partner Celgene Corporation has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein under the terms of the 2010 collaboration agreement. This would be the second IDH mutant inhibitor to be licensed by Celgene in less than a year. AG-120 is currently being evaluated in two Phase 1 dose escalation trials, one in advanced hematologic malignancies and the other in advanced solid tumors. Both trials are evaluating AG-120 in patients whose cancer harbors an IDH1 mutation. The first data from the AG-120 program were presented at the EORTC-NCI-AACR Symposium on November 19, 2014 in advanced hematologic malignancies. Agios expects to report the first data from the Phase 1 advanced solid tumor trial at a medical conference in 2015. Celgene's exercise of the option is subject to receipt of any required regulatory approvals including any applicable clearance under the Hart-Scott-Rodino Act. Agios is webcasting its corporate presentation from the 33 Annual J.P. Morgan Healthcare Conference today at 2:30 p.m. PST (5:30 p.m. EST). The presentation will be followed by a webcast of its question and answer session at 3:00 p.m. PST (6:00 p.m. EST).
JPM: 59.67 (+0.10), AGIO: 118.55 (+0.11), CELGZ: 3.17 (-0.04)
